anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an oral medicine for colorectal carcinoma fistulation later-stage nursing, and its preparation method. The medicine comprises 50-80 parts of Semen Phaseoli, 35-70 parts of Holothuria leucospilota, 40-90 parts of Meliosma fordii, 30-60 parts of roxburgh rose root, 24-60 parts of baccate sedge herb, 32-56 parts of shrubalthea root, 18-30 parts of radix paeoniae rubra, 22-46 parts of Inonotus cuticularis (Bull.: Fr.) Karst., 18-34 parts of konjac, 8-20 parts of Ajuga pantantha, 20-38 parts of Coriolus versicolor(L.ex Fr.)Quel., 20-50 parts of Cinnamomum wilsonii Gamble and 45-86 parts of Begonia yunnanensis Levl.. The medicine has strict composition and reasonable compatibility, has the efficacies of heat clearing, blood activating, diuresis inducing, channel freeing, intestine widening, qi rectifying, intestine damp heat removing, intestine moistening, bowel relaxing, blood circulation invigorating, bleeding stopping, qi moving, pain relieving, and stomach and intestine distention qi mitigating, comprises Chinese herbal medicines benefiting the rehabilitation of alimentary canal tumors and adjusting the immune function, can condition colorectal carcinoma patients subjected to fistulation, and has a good nursing efficacy on later-stage fistulization stoma complications.
This is a Phase 1, open-label, single center, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of high dose simvastatin in patients with GI cancers. Three dose levels will be evaluated. Simvastatin will be given at escalating dose of 7.5mg/kg bid, 10mg/kg bid and ( ) mg/kg bid for 7 days and off treatment for 14 days (Final dose will be determined based on PK data of cohort 1 and 2). The treatment will be repeated every 3 weeks. The cohort size of at least 3 and up to 6 patients ('rolling six design') will be employed to improve the rate of accrual of patients to cohorts close to the presumed therapeutic dose by reducing the need for late replacement of patients who become non-evaluable during the DLT assessment period, whilst not compromising collection of safety data. The total number of patients will depend upon the number of dose adjustments necessary. And intra-patient dose escalation is not allowed.
PREZISTA/ritonavir is not recommended in pediatric patients below 3 years of age because of toxicity and mortality observed in juvenile rats dosed with darunavir (from 20 mg/kg to 1000 mg/kg) up to days 23 to 26 of age [see Warnings and Precautions (5.10), Use in Specific Populations (8.1)and Clinical Pharmacology (12.3)] . 

The safety, pharmacokinetic profile, and virologic and immunologic responses of PREZISTA/ritonavir administered twice daily were evaluated in treatment-experienced HIV-1-infected pediatric subjects 3 to less than 18 years of age and weighting at least 10 kg. These subjects were evaluated in clinical trials TMC114-C212 (80 subjects, 6 to less than 18 years of age) and TMC114-228 (21 subjects, 3 to less than 6 years of age) [see Adverse Reactions (6.1), Clinical Pharmacology (12.3)and Clinical Studies (14.4)] . Frequency, type, and severity of adverse drug reactions in pediatric subjects were comparable to those observed in adults [see Adverse Reactions (6.1)] . Refer to Dosage and Administration (2.5)for twice-daily dosing recommendations for pediatric subjects 3 to less than 18 years of age and weighing at least 10 kg. 

In clinical trial TMC114-C230, the safety, pharmacokinetic profile and virologic and immunologic responses of PREZISTA/ritonavir administered once daily were evaluated in treatment-naïve HIV-1 infected pediatric subjects 12 to less than 18 years of age (12 subjects) [see Adverse Reactions (6.1), Clinical Pharmacology (12.3)and Clinical Studies (14.4)] . Frequency, type, and severity of adverse drug reactions in pediatric subjects were comparable to those observed in adults [see Adverse Reactions (6.1)] . Once daily dosing recommendations for pediatric patients 3 to less than 12 years of age were derived using population pharmacokinetic modeling and simulation. Although a PREZISTA/ritonavir once daily dosing pediatric trial was not conducted in children less than 12 years of age, there is sufficient clinical safety data to support the predicted PREZISTA exposures for the dosing recommendations in this age group [see Clinical Pharmacology (12.3)] . Please see Dosage and Administration (2.5)for once-daily dosing recommendations for pediatric subjects 3 to less than 18 years of age and weighing at least 10 kg. 

Juvenile Animal Data

In a juvenile toxicity study where rats were directly dosed with darunavir (up to 1000 mg/kg), deaths occurred from post-natal day 5 at plasma exposure levels ranging from 0.1 to 1.0 of the human exposure levels. In a 4-week rat toxicology study, when dosing was initiated on post-natal day 23 (the human equivalent of 2 to 3 years of age), no deaths were observed with a plasma exposure (in combination with ritonavir) 2 times the human plasma exposure levels.
Participants received placebo ELLIPTA DPI followed by placebo BREEZHALER DPI on Day 1. Participants were asked to complete the ease-of-use questionnaire and VAS on their willingness to continue with the inhaler after using each device. Participants also completed the preference questionnaire version 2 on Day 1.
PURPOSE:To enable the efficient absorption of kallikrein useful as a vasodilator, etc. through the rectum, without causing the deactivation of the compound, by forming kallikrein in the form of capsule, tablet, suppository, solution or suspension, and inserting or injecting the preparation into the anus. CONSTITUTION:Kallikrein which is a hormonelike substance secreted from the pancreas is used in a form suitable for the absorption through the rectum, i.e. in the form of capsule (its content may be powder, granule, jelly, plaster, etc.), tablet, suppository, etc. The deactivation of the active component and the problems in the drug preparation technique to prevent the deactivation can be solved by this process, and the absorption efficiency comparable or superior to that of the oral preparation can be expected.
Participants will be asked to follow TRE for 16 weeks with a protocol that is personalized to their preferences within the following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week. Participants receive support to follow the TRE intervention from the study team which will include an initial consultation with a registered dietitian and ongoing tailored feedback via brief support calls from study staff at weeks 1, 3, 6, and 12.
One of the most common surgical procedures performed in older adults is total knee arthroplasty (TKA), with an estimated 1 million TKAs performed annually in the United States. TKA directly addresses the pathology underlying knee joint pain and mobility limitations resulting from osteoarthritis. For most patients, TKA is effective for pain reduction and increasing function. However, a subgroup of 15-20% of TKA patients report unsatisfactory long-term pain outcomes well after postsurgical healing has occurred despite technical success of the procedure. Chronic postsurgical pain (CPSP) following TKA has been reported to be worse than the preoperative pain in 7% of TKA patients at up to 4-years. A potential biological mechanism is perioperative oxidative stress (OS),

The proposed project seeks to confirm the mechanistic role of OS in post-TKA CPSP and test the hypothesis that a perioperative intervention to reduce OS may reduce risk for CPSP post-TKA. This is a prospective randomized controlled trial that will assess preoperative, perioperative, and long-term oxidative stress (OS); pain; and functional outcomes over a 12 month period and test the hypothesis that a potent antioxidant intervention (GlyNAC) reduces OS and CPSP in patients undergoing total knee arthroplasty (TKA).
Clusters randomized to the control group will keep their usual practice standards. Patient screening will be performed at the outpatient clinics and primary care centers. Both groups must complete the following forms: "Admission", "06 months", and "12 months". Data collection will be performed from medical records by an independent professional not involved in patient care. Furthermore, study coordinator and data collectors from the sites, when asked, must provide appropriate documents for adjudication purposes.
An antigen/antibody specificity exchanger is disclosed. The exchanger comprises an amino-acid sequence of an antibody which specifically binds to a certain antigen linked to an amino-acid sequence to which a certain antibody binds. Also, a diagnostic reagent comprising an antigen/antibody specificity exchanger is disclosed. The reagent may be used, for example, instead of antisera or monoclonal antibodies in in vitro testing systems, such as immunological tests. Further, a method of treating a disease or disorder caused by a known antigen in an individual in need of an increased number of antigen-specific antibodies is disclosed. The method may be used, for example, to redirect a patient's antibodies against poliovirus to fight HIV infection.
Each individual will participate separately in four testing sessions. Each testing session will last for approximately 5 hours and will be separated by a minimum of one week. Participants will arrive at the Temple University GCRC or CORE at either 7:30 a.m. or 8:30 a.m. after an overnight fast (10-12 hours) to ensure that all participants are in the same metabolic state. Upon arrival the experimenter will ask participants to complete a pre-session questionnaire and rate their feelings of hunger and satiety on a visual analog scale (VAS). An indwelling catheter will be inserted in an antecubital vein by the study nurse and a baseline blood sample will be obtained for measurement of glucose and insulin concentrations. Glucose will be measured by the glucose oxidase method using a glucose analyzer and insulin will be measured by radioimmunoassay.

One of four isocaloric meals (see example below), varying in macronutrient content and GI value of foods, will be administered in random order at either 8:00 a.m. or 9:00 a.m. Energy density will be controlled. The meal and 8 ounces of water will be consumed within fifteen minutes. A short visual analog questionnaire will be distributed at the conclusion of the meal to rate the meal consumed. Blood samples will be taken 15 minutes after food consumption and at 30 minute intervals (i.e., 30, 60, 90, 120, 150, 180, 210, and 240 minutes) over four hours following administration of the meal. Four milliliters of blood will be collected at each time point (via indwelling catheter), resulting in a total of 40 milliliters of blood collected at each study session and 160 milliliters (i.e., 40 ml x 4 testing sessions) within an 8 week time period. Participants will be asked to rate their feelings of hunger at these time points. Following the last blood sample, participants will be given the opportunity to consume food ad libitum from a buffet style lunch. Based on known serving sizes and measurements of unconsumed food, the amount of food eaten and its associated energy content will be determined.
This is a pilot study with recruitment carried out in a single centre where participants will be assigned to receive Letrozole 2.5 mg once a day for 4 months. The following data will be collected: semen analyses, clinical history including smoking status, BMI, Y microdeletion, karyotype and FSH, LH, testosterone, E2, drug side effects and effects on libido. The following assessments will be performed before and 4 months after drug administration: sperm analyses, FSH, LH, E2 and testosterone measurements.

Prior to recruitment, the study participant would have undergone the routine investigations for evaluating azoospermia or severe oligozoospermia. These would include FSH, LH, testosterone, karyotyping, Y chromosome microdeletion genetic studies and at least 1 seminal analysis. Despite the availability of biochemical techniques to differentiate non-obstructive azoospermia (NOA) patients from obstructive azoospermia patients, fine needle aspiration (FNA) has been regarded as a highly informative and a minimally invasive method often routinely done in the investigation of azoospermia. All patients with NOA would have a FNA performed as part of their routine workup which would be done before recruitment and initiation of Letrozole. The safety of FNA use is also regarded as being supportive for the researchers against any possible patient lawsuits resulting from any impaired spermatogenesis induced by an off-label prescription. All oligozoospermic patients will be offered to have their sperm cryopreserved before drug administration. The investigations must have been performed within a 6 month time frame prior to recruitment.

There will be 3 clinic visits during the dosing period and 1 post dosing follow up visit. During the initial visit where recruitment into the study occurs, the participant will be prescribed the medication. One week later, a telephone interview will be conducted to review for side effects and arrange an early appointment at patient request. One month later, the participant will be reviewed in clinic and a side effect check list will be conducted. Telephone interviews will be conducted again at 2nd and 3rd month from administration of the drug. At 4th month from administration of the drug, the blood tests and semen analysis will be performed. It is likely that the participant will still be followed up for enrolment into IVF / ICSI programme should spontaneous pregnancy fail to occur. The window period for all clinic visits and telephone interviews is +/- 5 days.
PURPOSE: A composition containing soybean extract is provided to supply nutrient to epidermal cells of hair root, to prevent hair loss, and to promote hair growth. CONSTITUTION: A composition for preventing hair loss or promoting hair growth contains 0.001-90 wt% of soybean extract as an active ingredient, prepared by extracting 1-70%(v/v) C1-C5 alcohol. A composition for enhancing hair health contains the soybean extract as an active ingredient. The C1-C5 alcohols are methanol, ethanol, isopropyl alcohol, n-propyl alcohol, n-butanol, or isobutanol. The composition is applied to a cosmetic, food, or pharmaceutical composition. [Reference numerals] (AA) Control group; (BB) Embodiment 4; (CC) Embodiment 2
Disclosed are uses of microproteins preferably microproteins forming a cystine knot (i.e. belonging to the family of inhibitor cystine knot (ICK) polypeptides) or polynucleotides encoding said microproteins for the preparation of a pharmaceutical composition for treating or preventing a disease that can be treated or prevented by inhibiting the activity of tryptase as well as corresponding methods of treatment. Also disclosed are uses of the microproteins for inhibiting tryptase activity, for purifying tryptase, as a carrier molecule for tryptase and for deleting or quantifying tryptase in a sample, including corresponding diagnostic applications. Furthermore disclosed are fusion proteins comprising an inactive barnase as well as fusion proteins comprising barnase and a microprotein. Also encompassed are nucleic acid molecules encoding such a fusion protein, as well as corresponding vectors, host cells, preparation methods and uses of the fusion protein. Moreover, the present application discloses a crystal of a microprotein fused with barnase, preferably inactive barnase. The disclosure also refers to corresponding preparation methods for the crystal, structure analysis methods using the crystal data storage media comprising the structure data obtained, as well as to in silico methods using the structure data for characterizing the binding of microproteins to target molecules. Furthermore, disclosed are pharmaceutical compositions comprising the crystal and corresponding medical uses.
PROBLEM TO BE SOLVED: To provide a method of easily preparing phlorotannins in which various functions have been found to phlorotannins, if there is a simple preparing method, while that use advances further is expected, if the health of a diabetic patient or a person who has the risk can be recovered by an agent of a natural product origin of experienced food, those are very preferable.SOLUTION: The preparation method of phlorotannins includes: a process in which 2-10 pts.wt. of an ethanol-containing solvent is used for one pt.wt. of a dried product of brown algae raw material to be extracted, and an extract including phlorotannins is obtained; and a process in which 1.6-2.9 pts.wt. (desirably, 1.8-2.7 pts.wt., and further desirably, 2.0-2.5 pts.wt.) of activated carbon is added to 100 pts.wt. of the dried product of the brown algae raw material, and impurities are removed by adsorption. Moreover, a treatment medicinal of diabetes includes phlorotannins, fucoxanthin, magdisalicylate, and fucoidan.
Hydralazine Hydrochloride Injection, USP is an antihypertensive available in a 1 mL vial for intravenous and intramuscular administration. Each milliliter of the sterile, nonpyrogenic colorless solution contains Hydralazine Hydrochloride USP, 20 mg, Propylene Glycol USP, 103.6 mg, and Water for Injection q.s. The pH of the solution is 3.4 - 4.4. pH may be adjusted with Hydrochloric Acid and/or Sodium Hydroxide. Hydralazine Hydrochloride is 1-Hydrazinophthalazine monohydrochloride, and its structural formula is:

Molecular Formula C 8H 8N 4HCl 

Hydralazine Hydrochloride USP is a white to off-white, odorless crystalline powder. It is soluble in water, slightly soluble in alcohol, and very slightly soluble in ether. It melts at about 275°C, with decomposition, and has a molecular weight of 196.64.
A method and system to implement an electronic personal training is provided. According to an example embodiment, a method and system for recording, tracking, and providing personal goals for fitness and health-related activity using personal electronic devices that receive and store input from objects (e.g., exercise equipments or food items) in an environment (e.g., a fitness center or a supermarket) and output relevant personal information about the activity currently being input (e.g. on a digital screen, pre-stored version of a human voice, etc.). The portable electronic devices may periodically communicate data with a system located on a communications network, where the fitness data may be processed to provide individual and group reports (e.g. email sent to person, membership trends to gyms, account history available online). A user may set or modify his or her goals by accessing the system via the portable electronic device or a user computer.
Control participants will complete an attention-matched internet stress reduction paradigm, which includes an internet navigation protocol and placebo computer games. As with the intervention group, participants in the control group will come to the lab for four two-hour weekly sessions in small groups of 3-4. Facilitator involvement will be the same as the intervention group (e.g., the research assistant will explain computer activities and games but will otherwise not interact with the participant).
To determine the effect of pre-existing filarial infection and its treatment on viral burden and clinical parameters in patients infected with HIV, this study aims to follow plasma HIV loads, CD4 counts, and clinical parameters in a population of HIV-infected individuals co-infected with Wuchereria bancrofti, prior to and after treatment of filarial infection. The study individuals will be drawn from the patient cohort followed by the HIV Clinic at the Government General Hospital and the Tuberculosis Research Centre, Chennai, India, or those from YRG-Care (Chennai, India), an area endemic for lymphatic filariasis (LF) and where the prevalence of HIV infection in the general population is about 7%. These patients are adults of all ages, both males and females, come from the states of Tamil Nadu and Andhra Pradhesh. Having established as part of a previous protocol (01-I-N022) an HIV/filarial coprevalence of 6-10% based on W. bancrofti circulating antigen detection in HIV-positive and -negative individuals, patients in whom co-infection with HIV and LF has been diagnosed will be paired with two HIV-positive (but filarial antigen negative) clinic controls matched for age, gender, viral load antiretroviral therapy and CD4 count. All efforts will be made to connect study participants with programs for antiretroviral distribution. Within a month of a baseline clinical evaluation, patients and controls will receive a single dose of the combination of diethylcarbamazine/albendazole (the drug combination given as part of national campaigns to eliminate LF) and will then be followed with viral loads, CD4 counts and clinical examinations at one week, as well as 1, 3, 6 and 12 months after the administration. By assessing these changes, the influence of a co-existing filarial infection on plasma HIV viral load, CD4 count and clinical course can be determined. At the end of the study period, all participants will be re-assessed for filarial antibody and antigen to ensure absence of the parasite. Any patient who has evidence of ongoing filarial infection with W. bancrofti will be re-treated with DEC/albendazole.
FIELD: medicine, veterinary science. ^ SUBSTANCE: method of improving a cartilage involving condition and reducing the related defects in an animal, including; introduction to said animal of effective amount of sulphur amino acid which makes at least 1.2 wt % and effective amount of manganese which makes at least 50 p/mln and higher of dry weight. The method for prevention of cartilage degradation in the animal includes feeding of said animal with a composition including sulphur amino acid and manganese. A composition for improving the cartilage involving condition and reducing the related defects in the animal, containing: effective amount of sulphur amino acids which makes at least 1.2 wt % and effective amount of manganese which makes at least 50 p/mln and higher of dry weight. ^ EFFECT: invention provides reduction of the visually observed cartilage defects. ^ 22 cl, 6 tbl, 2 ex
PCT No. PCT/FR96/01437 Sec. 371 Date Dec. 30, 1997 Sec. 102(e) Date Dec. 30, 1997 PCT Filed Sep. 16, 1996 PCT Pub. No. WO97/12587 PCT Pub. Date Apr. 10, 1997A cosmetic or dermatological composition for treating keratinous material, particularly human hair, including a cosmetically or dermatologically acceptable medium containing at least one silicone-grafted polymer with a polysiloxane portion and a portion consisting of a non-silicone organic chain, wherein one of the two portions constitutes the main polymeric chain while the other is grafted onto said main chain, an at least one selected fatty-chain amide. Such compositions are particularly suitable for use as rinsable or non-rinsable products for washing and conditioning hair, hair setting or hair styling.